Table 3. One way sensitivity analysis and other analysis results.
| Comparison | Parameter | Value | ICER | Comparison | Parameter | Value | ICER |
|---|---|---|---|---|---|---|---|
| QV Vs. NV | Efficacy Bivalent Vaccine | 0.9 | 24210 | BV Vs. NV | Cost Bivalent Vaccine | one hundred and thirty-three US Dollars | 17258 |
| BV Vs. NV | 28727 | QV Vs. NV | 24210 | ||||
| BV Vs QV | BV Vs QV | QV dominated | |||||
| QV Vs. NV | 1 | 24210 | QV Vs. NV | four hundred and eighty-seven US Dollars | 24210 | ||
| BV Vs. NV | 25048 | BV Vs. NV | 67404 | ||||
| BV Vs QV | 32548 | BV Vs QV | BV dominated | ||||
| BV Vs. NV | Efficacy Quadrivalent Vaccine | 0.338 | 28727 | QV Vs. NV | Cost Quadrivalent Vaccine | one hundred and fifty-seven US Dollars | 19763 |
| QV Vs. NV | 80519 | BV Vs. NV | 28727 | ||||
| QV Vs BV | 847 | BV Vs QV | BV dominated | ||||
| QV Vs. NV | 0.984 | 21439 | BV Vs. NV | two hundred and eighty-two US Dollars | 28727 | ||
| BV Vs. NV | 28727 | QV Vs. NV | 37549 | ||||
| BV Vs QV | 56118 | BV Vs QV | QV dominated | ||||
| QV Vs. NV | Discount Of Costs | 0 | 9262 | QV Vs. NV | Discount of Health Outcomes | 0 | 6162 |
| BV Vs. NV | 14338 | BV Vs. NV | 7311 | ||||
| NV Vs. BV | 6% | 29042 | BV Vs. NV | 6% | 80795 | ||
| NV Vs. QV | 33308 | QV Vs. NV | 95871 | ||||
| QV Vs. NV | Vaccination Coverage | 0.5 | 24300 | QV Vs. NV | Protection Duration | 30 Years | 40082 |
| BV Vs. NV | 29069 | BV Vs. NV | 46757 | ||||
| BV Vs. NV | 1 | 24245 | QV Vs. NV | 70 Years | 24210 | ||
| QV Vs. NV | 28629 | BV Vs. NV | 28727 | ||||
| QV Vs. NV | Screening Coverage | 0 | 4976 | QV Vs. NV | Cross Protection | 13835 | |
| BV Vs. NV | 5942 | BV Vs. NV | 16986 | ||||
| QV Vs. NV | 1 | 32462 | NV: Non Vaccination – Screening Alone; BV: Bivalent Vaccine; QV Quadrivalent Vaccine; A vs. B means that B is used as reference to calculate the ICER. | ||||
| BV Vs. NV | 38761 | ||||||